Primary sclerosing cholangitis (PSC) is a rare non-communicable disorder that affects the liver. Chronic inflammation in and around the bile duct is followed by the development of fibrotic ...

Phase 2 study in cholestatic liver diseases, focused on PBC and PSC, anticipated to initiate in Q1 2027 –– Builds on completed Phase 1a study ...

Primary Sclerosing Cholangitis (PSC) is a debilitating rare disease of the liver with no effective treatment. Researchers have now identified four regions of the genome associated with the disease, ...

Quantitative MRCP improved PSC prognostic performance in an international study, supporting future risk models and trials.

Primary Sclerosing Cholangitis is an orphan disease with no FDA approved therapeutic options or viable alternatives except surgical interventions. PSC is caused by dysregulation of bile homeostasis ...

Coffee and cigarette smoking may protect against the rare liver disease Primary Sclerosing Cholangitis (PSC), study shows. Coffee and cigarette smoking may protect against the rare liver disease ...

Table 1 Association summary statistics across four newly associated PSC risk loci Figure 1: Odds ratios (and their 95% confidence intervals) for PSC, UC and CD across the six PSC-associated SNPs ...

The last time I spoke about Mirum Pharmaceuticals, Inc. (MIRM) it was in a Seeking Alpha article entitled "Mirum Pharmaceuticals: After Phase 2 Miss, An iBAT Inhibitor On Deck To Drive Value." With ...